Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Evgen Pharma ( (GB:TCF) ).
TheraCryf plc announced the successful initiation of manufacturing scale-up for its lead asset, Ox-1, an orexin 1 antagonist targeting addictive behaviors. This milestone, achieved in partnership with Pharmaron, marks a significant step towards clinical readiness, with the production of demonstration and toxicology batches essential for regulatory documentation. This progress underscores TheraCryf’s strategic focus on unlocking the potential of its addiction program, addressing a large market opportunity.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focused on brain disorders, with a diverse pipeline targeting conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data for preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is listed on AIM in London under the ticker symbol TCF.
Average Trading Volume: 2,328,340
Technical Sentiment Signal: Sell
Current Market Cap: £5.48M
Learn more about TCF stock on TipRanks’ Stock Analysis page.